Cadila Looks at Alternative to Roche’s Rs 60k Antibodies Cocktail
Seeks DCGI nod for Phase 1 of 3-phase clinical trials of two SARS-CoV-2-neutralising monoclonal antibodies
Advertisement*
Most Read
Advertisement*
Advertisement*